BPC-157 Argininate 500 mcg
$64.92$162.30 (-60%)
BPC-157 Argininate 500 mcg: BPC-157 Argininate is a formulation designation that includes the BPC-157 peptide and an arginine-related form. BPC-157 itself is a fifteen-residue synthetic peptide. The argininate wording must remain part of the supplied material’s identity; it should not be dropped when comparing certificates, formulation records or a laboratory purchase specification. This listing uses a capsule presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.
BPC-157 Argininate 500 mcg Australia
BPC-157 Argininate 500 mcg is listed at AU Peptides Shop in a capsule presentation. This page brings together the compound identity, reference chemistry and laboratory considerations relevant to this specific catalogue entry. It is intended exclusively for controlled in vitro laboratory research, not personal use.
Product description
BPC-157 Argininate is a formulation designation that includes the BPC-157 peptide and an arginine-related form. BPC-157 itself is a fifteen-residue synthetic peptide. The argininate wording must remain part of the supplied material’s identity; it should not be dropped when comparing certificates, formulation records or a laboratory purchase specification.
The parent peptide’s molecular formula and reference mass do not specify the complete argininate preparation. Arginine association, counterions, water and excipients can affect the supplied composition. A capsule or tablet matrix also requires a different sample-preparation validation from an unformulated peptide.
Chemical information and molecular structure
| Reference designation | BPC-157 Argininate |
|---|---|
| Parent reference species | Bpc-157 |
| Parent reference formula | C62H98N16O22 |
| Parent reference molecular weight | 1419.5 g/mol |
| Reference identifier | PubChem CID 9941957 |
| Sequence information | Parent BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
View the parent reference molecular structure in PubChem. The referenced structure identifies a database species; it is not a structural analysis or certificate for the supplied BPC-157 Argininate 500 mcg.
Reference formula and molecular weight depend on the represented chemical species. Counterions, hydration, oxidation state, terminal modifications and formulation ingredients can change the relationship between a database molecule and the supplied material. Use the named reference species for structural comparison, and use the batch specification for the actual product composition.
Research applications and experimental scope
- Parent-peptide identification in an argininate-labelled material.
- Formulation and excipient characterisation.
- Extraction recovery from a finished presentation.
- Comparative stability assessment using defined sample conditions.
These are laboratory research topics and analytical objectives, not claims that the supplied product has achieved a biological result. Define the experimental question, model and acceptance criteria before comparing materials. A literature observation made with a different sequence, formulation or model cannot establish the performance of this catalogue item.
Analytical characterisation
For BPC-157 Argininate, sequence-sensitive identification and chromatographic profiling answer different questions. A compatible intact mass supports a molecular comparison, while a suitable mapping or fragmentation method may provide additional sequence evidence. A chromatographic peak area alone does not confirm every residue, terminal group or stereochemical feature.
Use reference material that matches the sequence and modifications being evaluated. Separate the identification question from the measurement of impurities, water, counterions or peptide content. A single percentage should retain the method and reporting basis under which it was obtained; it should not be expanded into an unsupported claim about sterility, activity or total material composition.
Laboratory model and control considerations
An in vitro experiment with BPC-157 Argininate should distinguish the test-material response from effects of the vehicle, assay matrix and any additional ingredients. Include the controls appropriate to the study design, and keep the reference standard and test sample traceable to their own preparation records. Where a readout depends on cell viability or matrix composition, assess those factors independently of the primary measurement.
Record the sample identity, selected product option, preparation history and analytical method used for the comparison. Repeatability within one run does not by itself establish specificity or transferability to another model. Report observations within the limits of the experimental system rather than treating an in vitro result as evidence of a clinical benefit.
Supplied format and product specifications
| Product name | BPC-157 Argininate 500 mcg |
|---|---|
| Catalogue format | capsule presentation |
| Quantity wording in listing | 500 mcg |
| Purity / certification | Refer to the relevant batch report; no percentage or certification is assigned without product documentation. |
A capsule-format listing must be evaluated as a finished presentation. Ingredient amount, capsule count and excipient composition are separate specifications. Do not describe a capsule as a vial of lyophilized powder. Laboratory analysis of this presentation may require validation of extraction recovery and evaluation of the capsule matrix.
Solubility and matrix compatibility
For BPC-157 Argininate, use product-specific solubility information and a laboratory method appropriate to the selected presentation. Apparent dispersion is not necessarily complete dissolution, and a visually clear preparation does not establish chemical stability. Assess recovery and matrix compatibility using the measurement required for your experiment.
Where the product contains additional ingredients, distinguish dissolution of the reference compound from extraction of the finished formulation. Record the documented matrix and any observed interference so another analyst can interpret the result. No universal solvent, solubility limit or preparation protocol is assigned from this catalogue name.
Storage and handling
Use the storage conditions specified for the supplied BPC-157 Argininate 500 mcg batch and presentation. A universal freezer temperature, refrigeration interval or prepared-sample expiry is not assigned from the compound name alone. Obtain the relevant product guidance when storage or sample stability is an acceptance criterion for your work.
Maintain traceable labels and document the handling history relevant to the study. Assess changes in appearance, analytical profile or recovery against a validated method rather than assuming that an unchanged label establishes stability. Aseptic laboratory technique does not by itself demonstrate that a research product is sterile; sterility and related quality attributes require their own evidence.
Related catalogue comparisons
- ARG BPC-157 — Same named compound(s), different format.
- BPC-157 5mg/10mg — Different designation; compare identity separately.
- BPC157 10mg+GHK-CU 50mg+TB500 10mg Glow blend — Different designation; compare identity separately.
- TB-500 + BPC-157 Mix 5mg / 5mg Wolverine stack — Different designation; compare identity separately.
Compare the exact compound, form and quantity in each linked listing. These catalogue relationships do not establish interchangeable materials or recommend combined use.
Australian research enquiries
For BPC-157 Argininate 500 mcg in Australia, include the complete listing name, required option and any analytical documentation requirements when you contact AU Peptides Shop. Browse the research catalogue for other individually specified materials. Current purchasing options show price and availability; batch evidence should be reviewed separately.
Scientific references
Research compliance notice
For controlled in vitro laboratory research only. Not for human or veterinary use. This description provides scientific reference information and does not recommend dosing, administration or treatment. Research-use labelling does not establish regulatory approval or permission for a particular activity under Australian therapeutic-goods requirements.
